The mammalian target of rapamycin (mTOR) plays a central role in regulating the proliferation of malignant glioma cells, and mTOR-specific inhibitors such as rapamycin analogs are considered as promising therapy for malignant gliomas. However, the efficacy of mTOR inhibitors alone in the treatment of patients with malignant gliomas is only modest, potentially because these agents rather than acting as mTOR kinase inhibitors instead interfere with the function of only mTOR/raptor (regulatory-associated protein of mTOR) complex and thus do not perturb all mTOR functions. The purpose of this study was to determine whether global inhibition of the mTOR molecule enhances the antitumor effect of rapamycin on malignant glioma cells. We showed that rapamycin induced autophagy and that inhibition of autophagy by small interfering RNA (siRNA) directed against autophagyrelated gene Beclin 1 attenuated the cytotoxicity of rapamycin in rapamycin-sensitive tumor cells, indicating that the autophagy was a primary mediator of rapamycin's antitumor effect rather than a protective response. Exogenous expression of an mTOR mutant interfering with its kinase activity markedly enhanced the incidence of rapamycin-induced autophagy. Moreover, silencing of mTOR with siRNA augmented the inhibitory effect of rapamycin on tumor cell viability by stimulating autophagy. Importantly, not only rapamycin-sensitive malignant glioma cells with PTEN mutations but also rapamycin-resistant malignant glioma cells with wild-type PTEN were sensitized to rapamycin by mTOR siRNA. These results indicate that rapamycin-induced autophagy is one of the agent's antitumor effects and that silencing or inhibiting mTOR kinase activity could enhance the effectiveness of rapamycin.
Introduction
Malignant gliomas are among the most devastating cancers (Surawicz et al., 1998) . Because these tumors rapidly grow and invade the surrounding brain parenchyma, it is often impossible to achieve complete surgical resection without causing severe neurologic damage. Malignant gliomas have a dismal prognosis: the median overall survival duration of patients after diagnosis is 12-15 months despite the multidisciplinary use of surgery, chemotherapy and radiotherapy (Mitchell et al., 2005) . Novel therapeutic agents for malignant gliomas are sorely needed.
The phosphatidylinositol 3-phosphate kinase (PI3K)/ protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling pathway is crucial for cell proliferation, survival and migration (Vogt, 2001; Oldham and Hafen, 2003) . Dysregulation of this pathway occurs in various cancers (Sekulic et al., 2000; Vogt, 2001) , and inhibition of PI3K/Akt/mTOR signaling is considered an attractive strategy for treating diverse cancers (Vivanco and Sawyers, 2002) . In particular, mTOR is regarded as an essential molecule in maintaining the transformed phenotype and therefore in regulating the sensitivity of cancer cells to mTOR inhibitors (Bjornsti and Houghton, 2004) . Rapamycin and its derivatives, such as CCI-779, RAD001 and AP23573, specifically bind to the intracellular FKBP12 protein to form a drug-receptor complex that then interacts with and suppresses mTOR, resulting in inactivation of its downstream molecule p70S6 kinase (p70S6K) (Huang and Houghton, 2003; Sawyers, 2003) . Accumulating results from phase I and II trials suggest that the inhibition of mTOR signaling could be exploited as a cancer-specific therapy (Peralba et al., 2003) . However, these agents alone were only mildly effective in patients with malignant gliomas, and only 36% of the patients showed improvement on neuroimaging (Galanis et al., 2005) . The resistance to mTOR inhibitors underscores the need to explore a novel means of sensitizing this disease to treatment with mTOR inhibitors.
A recent investigation showed that cellular treatment with rapamycin does not lead to irreversible inhibition of mTOR kinase activity because the FKBP12-rapamycin binding domain of mTOR lies outside of the catalytic domain (Edinger et al., 2003) . Moreover, rapamycin does not inhibit all mTOR functions, because mTOR exists in cells at least two distinct multiprotein complexes and only one of which binds to FKBP12-rapamycin (Loewith et al., 2002) . The rapamycin-sensitive complex is defined by the interaction of mTOR with the accessory protein raptor (regulatory-associated protein of mTOR), and the rapamycin-insensitive complex interacts with rictor (rapamycin-insensitive companion of mTOR) (Guertin and Sabatini, 2005) . On the basis of these observations, we speculated that global inhibition of the mTOR molecule would enhance the cytotoxic effect of rapamycin. To test our hypothesis, we treated rapamycinsensitive and rapamycin-resistant malignant glioma cells with small interfering RNA (siRNA) directed against mTOR in the presence of rapamycin. Silencing of mTOR augmented the effect of rapamycin in tumor cells regardless of the cells' intrinsic sensitivity to rapamycin. Enhancement of rapamycin-induced autophagy or type II programmed cell death appears to be the critical mediator. Our findings suggest that silencing mTOR signaling can sensitize malignant glioma cells to rapamycin.
Results
Effect of rapamycin on the cell viability of malignant glioma cells with mutant or wild-type PTEN Accumulating evidence indicates that rapamycin is particularly effective against tumors with constitutively activation of the PI3K pathway such as that occurs with mutational inactivation of PTEN (Guertin and Sabatini, 2005) . Therefore, we used four established malignant glioma cell lines, three with mutant PTEN (U87-MG, A172 and D54) and one with wild-type PTEN (LN229), to examine the antitumor effect of rapamycin. To assess the inhibitory effect of rapamycin, all four cell lines were treated with 1, 10 and 100 nM rapamycin for 48 h or with 100 nM rapamycin for 24 or 48 h and then subjected to the WST-1 cell viability assay. As shown in Figure 1a , the cell viability of the lines with mutant PTEN was moderately inhibited by rapamycin in dose-and timedependent manners, whereas LN229 cells were resistant to rapamycin even at a high concentration of 100 nM for 48 h. Thus, as we predicted, tumor cells with wild-type PTEN were more resistant to rapamycin than were tumor cells with mutant PTEN.
To investigate whether the variations in sensitivity to rapamycin were due to rapamycin's effect on mTOR signaling in tumor cells, we assessed the -specific 4E-BP1. Anti-total p70S6K or total 4E-BP1 antibody was used to confirm equal loading of proteins.
Effect of mTOR siRNA on rapamycin-induced autophagy A Iwamaru et al phosphorylation of two downstream targets of mTOR, p70S6K and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1), by using Western blotting. We found that rapamycin effectively inhibited the phosphorylation of p70S6K in both rapamycin-sensitive U87-MG cells and rapamycin-resistant LN229 cells (Figure 1b) . In U87-MG cells, treatment with rapamycin even at the lowest concentration of 1 nM for 48 h (BIC 85 ; concentration resulting in cell viability in 85% of control) or at 100 nM for 24 or 48 h (BIC 80 ) remarkably inhibited p70S6K phosphorylation, and in LN229 cells, treatment with rapamycin at 1 nM for 48 h (BIC 95 ) almost completely suppressed p70S6K phosphorylation. Interestingly, the phosphorylation of 4E-BP1 was not inhibited by rapamycin treatment (Figure 1c ). These results indicated that the antitumor effect of rapamycin is modest even for malignant glioma cells without PTEN function. Further, the inhibitory effect of rapamycin on the phosphorylation of p70S6K but not 4E-BP1 was apparent regardless of the sensitivity of tumor cells to rapamycin suggesting that rapamycin's inhibitory effect on mTOR function is partial and is not sufficient to induce robust growth inhibition.
Induction of autophagy in malignant glioma cells by rapamycin Autophagy is detected in a variety of cells treated with rapamycin (Noda and Ohsumi, 1998; Gutierrez et al., 2004; Kanazawa et al., 2004; Ravikumar et al., 2004) . We used electron microscopic analysis to determine whether rapamycin induces autophagy in our malignant glioma cells. Numerous autophagic vacuoles were observed in U87-MG cells treated with 100 nM rapamycin for 48 h, whereas U87-MG cells treated with vehicle alone for 48 h exhibited few autophagic features (Figure 2a ). There was no chromatin condensation or fragmentation, which is characteristic of apoptosis, in rapamycin-treated U87-MG cells.
We also assessed the presence of a punctate pattern of the green fluorescent protein (GFP)-tagged microtubuleassociated protein light chain 3 (LC3) (GFP-LC3) expression to determine whether rapamycin induces autophagy in malignant glioma cells. U87-MG cells were transiently transfected with GFP-LC3 expression vector for 24 h and then treated with vehicle alone or rapamycin (100 nM) for an additional 48 h, as described previously . Under a fluorescence microscope, the vast majority of the Effect of mTOR siRNA on rapamycin-induced autophagy A Iwamaru et al GFP-LC3-transfected cells showed diffuse distribution of GFP-LC3 in the absence of rapamycin, whereas treatment with rapamycin often resulted in a punctate pattern of GFP-LC3 fluorescence (Figure 2b ). This pattern represents the presence of autophagic vacuoles and indicated that LC3 is recruited to autophagic vacuoles in U87-MG cells treated with rapamycin. Quantification of autophagic cells revealed that compared with vehicle alone, treatment with rapamycin significantly increased the incidence of autophagy in U87-MG cells (10 versus 32%), A172 cells (10 versus 30%), D54 cells (10 versus 26%) and LN229 cells (7 versus 20%) (Po0.01 for all cell lines) (Figure 2c ). The prevalence of autophagy was lower in rapamycintreated LN229 cells than in other rapamycin-treated cells. These results indicated that rapamycin induces autophagy in malignant glioma cells and that the extent of autophagy induction might be related to their sensitivity to rapamycin.
Effect of inhibiting rapamycin-induced autophagy by Beclin 1 siRNA on malignant glioma cells Whether cancer treatment-induced autophagy mediates anticancer activity or functions as a protective reaction against the treatment remains controversial (OgierDenis and Codogno, 2003; Gozuacik and Kimchi, 2004; Kondo et al., 2005) . To assess the role of autophagy in rapamycin cytotoxicity, we determined whether inhibition of autophagy alters rapamycininduced cytotoxicity. U87-MG cells were transfected with 100 nM non-targeting (random) siRNA or Beclin 1 siRNA for 72 h in the presence of Oligofectamine and subjected to Western blotting using anti-Beclin 1 antibody. Beclin 1 is a mammalian homologue of yeast Atg6, which is necessary for autophagy to proceed in response to nutrient deprivation (Liang et al., 1999) . We observed that transfection with Beclin 1 siRNA markedly suppressed the expression of Beclin 1 protein relative to transfection with random siRNA (Figure 3a) .
To determine the effect of Beclin 1 siRNA transfection on rapamycin-induced autophagy, U87-MG and LN229 cells transiently transfected with the GFP-LC3 vector for 24 h were transfected with random siRNA or Beclin 1 siRNA for an additional 48 h. After that, the transfected cells were treated with vehicle alone or 100 nM rapamycin for 48 h and observed with fluorescence microscopy, and autophagic cells were quantified. Relative to the induction of autophagy by rapamycin alone, the prevalence of autophagic cells was significantly reduced by Beclin 1 siRNA transfection (32 versus 8% in U87-MG cells, Po0.01; 19 versus 13% in LN229 cells, Po0.05), whereas transfection with random siRNA did not significantly affect autophagy Effect of mTOR siRNA on rapamycin-induced autophagy A Iwamaru et al induction caused by rapamycin ( Figure 3b ). We also determined whether the cytotoxic effect of rapamycin was affected by Beclin 1 siRNA transfection. After transfection with 100 nM random siRNA or Beclin 1 siRNA for 48 h, U87-MG and LN229 cells were treated with vehicle alone or rapamycin (10 or 100 nM) for another 48 h for the cell viability assay. Transfection with Beclin 1 siRNA significantly attenuated the inhibitory effect of 100 nM rapamycin on the viability of U87-MG cells relative to random siRNA (83 versus 99%, Po0.01) (Figure 3c ). However, Beclin 1 siRNA transfection did not increase the incidence of apoptosis in rapamycin-treated U87-MG cells (data not shown). On the other hand, inhibition of autophagy by Beclin 1 siRNA did not affect the viability of LN229 cells treated with rapamycin (Figure 3c ), suggesting that autophagy might be not rather protective in LN229 cells. These results indicated that rapamycin-induced autophagy mediates the growth inhibitory activity of rapamycin in rapamycin-sensitive tumor cells, suggesting that stimulation of the autophagy caused by rapamycin should correspond to augmentation of its antitumor effect.
Involvement of mTOR catalytic activity in rapamycininduced autophagy
Because the domain of the mTOR that binds the complex of the immunophilin FKBP12 and rapamycin lies outside of the catalytic domain (Edinger et al., 2003) , treatment with rapamycin may inhibit the phosphorylation of p70S6K but may not globally block the catalytic activity of the mTOR. Therefore, we determined the inhibitory effect of rapamycin on mTOR kinase activity in malignant glioma cells. As shown in Figure 4a , although the phosphorylation of p70S6K was suppressed to an undetectable level in U87-MG cells by treatment with 100 nM rapamycin for 48 h, mTOR catalytic activity was not inhibited. A PI3K inhibitor LY294002 (5 mM, 24 h), which we used as a negative control (Takeuchi et al., 2005) , remarkably suppressed the phosphorylation of p70S6K and the mTOR catalytic activity. These results suggested that the cellular effects of rapamycin are not mediated through the suppression of mTOR kinase activity.
To determine whether the inhibition of mTOR kinase activity affects rapamycin-induced autophagy, U87-MG cells were transiently transfected with the expression vector containing the AU1-tagged kinase-inactive mTOR mutant (mTOR SIDA), which acts as a dominant-negative, or the AU1-tagged mTOR mutant (mTOR SI), which has reduced binding affinity for FKBP12-rapamycin complex and is catalytically active, and GFP-LC3 in the presence or absence of rapamycin. As shown in Figure 4b , transfection of U87-MG cells with mTOR SIDA or mTOR SI induced the expression of AU1 protein and increased the expression level of mTOR protein compared with parental U87-MG cells. Treatment with 100 nM rapamycin for 48 h, transfection with 1 mg mTOR SIDA for 72 h and their combination induced some cells to become autophagic (data not shown). Quantification of autophagic U87-MG cells showed that the prevalence of autophagy was 28% in U87-MG cells treated with rapamycin, 30% in cells transfected with mTOR SIDA and 50% in cells Figure 4 Involvement of mTOR kinase activity in rapamycin-induced autophagy of U87-MG cells. (a) Lack of inhibitory effect of rapamycin on mTOR kinase activity. Cells were treated with vehicle alone, 100 nM rapamycin for 48 h or 5 mM LY294002 for 24 h, and then lysed for immunoblotting (WB) with antibody against phospho-Thr 389 -specific p70S6K or for immunoprecipitation with mTOR antibody for mTOR kinase activity assay. Anti-total p70S6K antibody was used to confirm equal loading of proteins. (b) Transfection with mTOR mutants. After transfection with AU1-tagged mTOR SI or mTOR SIDA for 48 h, U87-MG cells were lysed and processed for immunoblotting with antibody against AU1 or mTOR. Anti-b-actin antibody was used to confirm equal loading of proteins. (c) Quantification of the rate of cells with GFP-LC3 dots in rapamycin-and mTOR mutants-treated cells. U87-MG cells were treated with vehicle alone, 100 nM rapamycin for 48 h, transfected with mTOR SIDA or mTOR SI for 48 h, or exposed to both rapamycin and mTOR SIDA or mTOR SI. Results shown are the means7s.d.s of three independent experiments. *Po0.01 and **Po0.05, compared with rapamycin alone.
Effect of mTOR siRNA on rapamycin-induced autophagy A Iwamaru et al subjected to both (Figure 4d ). Disruption of mTOR kinase activity by overexpression of the mTOR SIDA dominant negative significantly enhanced the incidence of rapamycin-induced autophagy versus rapamycin alone (Po0.01). In contrast, the prevalence of autophagy was 13 or 17% in U87-MG cells transfected with mTOR SI without or with rapamycin ( Figure 4d ). U87-MG cells expressing SI mTOR were highly resistant to rapamycin-induced autophagy (Po0.05), suggesting that the effect of rapamycin on autophagy is solely dependent on mTOR. These results indicated that the inhibitory effect of rapamycin does not block mTOR kinase activity and further that direct inhibition of the mTOR kinase increased the effect of rapamycin on induction of autophagy.
Effect of mTOR siRNA on malignant glioma cells with mutant or wild-type PTEN Because the transfection of mTOR SIDA vector is not practical for clinical application, we decided to disrupt the mTOR molecule by using siRNA. To determine whether mTOR siRNA transfection effectively inhibits the expression of mTOR protein in malignant glioma cells, we transfected tumor cells with 100 nM non-targeting (random) siRNA or mTOR siRNA for 72 h and subjected them to Western blotting. As shown in Figure 5a , the expression of mTOR protein was markedly decreased in U87-MG cells by mTOR siRNA compared with random siRNA. A similar inhibitory effect of mTOR siRNA on mTOR protein expression was Effect of mTOR siRNA on rapamycin-induced autophagy A Iwamaru et al observed in A172, D54 and LN229 cells (data not shown).
We then performed the WST-1 cell viability assay using tumor cells transfected with 100 nM random siRNA or mTOR siRNA for 72 h. The cell viability of the rapamycin-sensitive U87-MG, A172 and D54 cells and even the rapamycin-resistant LN229 cells was significantly inhibited by mTOR siRNA compared with random siRNA (Po0.01 for all cell lines) (Figure 5b ). These results indicated that 100 nM mTOR siRNA can inhibit the growth of malignant glioma cells regardless of PTEN status.
As a next step, we determined whether mTOR siRNA transfection induces autophagy in malignant glioma cells. As shown in Figure 5c , autophagic vacuoles were frequently observed in U87-MG cells transfected with Effect of mTOR siRNA on rapamycin-induced autophagy A Iwamaru et al 100 nM mTOR siRNA for 72 h compared with random siRNA. As we found for rapamycin treatment, there was no chromatin condensation or fragmentation characteristic of apoptosis. We also assessed the incidence of autophagic cells by using GFP-LC3 plasmid transfection. As shown in Figure 5d , U87-MG cells treated with Oligofectamine alone or transfected with 100 nM random siRNA for 72 h showed diffuse distribution of green fluorescence, whereas transfection with 100 nM mTOR siRNA for 72 h induced a punctate pattern of GFP-LC3 expression. Quantification of autophagic cells showed that compared with random siRNA, the prevalence of mTOR siRNA-transfected autophagic cells increased in U87-MG cells (20 versus 50%), A172 cells (14 versus 48%), D54 cells (15 versus 46%) and LN229 cells (22 versus 48%) (Po0.01 for all cell lines) (Figure 5e ). These results indicated that the inhibitory effect of mTOR siRNA on tumor cell viability is through the induction of autophagy.
Enhancement of the rapamycin-induced antitumor effect on malignant glioma cells by mTOR siRNA
Because mTOR siRNA induces autophagy in malignant glioma cells, we speculated that mTOR siRNA might enhance the antitumor effect of rapamycin by stimulating the autophagic pathway. To test our hypothesis, we transfected malignant glioma cells with 100 nM mTOR siRNA for 24 h and then treated them with vehicle alone or with 100 nM rapamycin for 48 h for the WST-1 cell viability assay. As shown in Figure 6a , the cell viability of U87, A172, D54 and LN229 cells was most inhibited by the combination of rapamycin and mTOR siRNA, and this combined effect was significant compared with rapamycin alone or mTOR siRNA alone (Pp0.01 for all comparisons). We also assessed the enhancement of autophagy by transfecting tumor cells with the GFP-LC3 expression vector before treatment with 100 nM rapamycin or transfection with 100 nM mTOR siRNA. Quantification of autophagic cells revealed that relative to vehicle alone, the combination therapy increased the prevalence of autophagic cells to 64% in U87-MG cells, 70% in A172 cells, 60% in D54 cells and 56% in LN229 cells (Figure 6b ). Transfection with mTOR siRNA significantly increased the incidence of rapamycininduced autophagy compared with rapamycin alone or mTOR siRNA alone (Pp0.02 for all comparisons). These results indicated that mTOR siRNA increases the antitumor effects of rapamycin on not only rapamycinsensitive U87-MG, A172 and D54 cells but also rapamycin-resistant LN229 cells by stimulating the induction of autophagy.
To determine the role of autophagy in the loss of cell survival caused by rapamycin and mTOR siRNA, we inhibited the autophagy using Beclin 1 siRNA as described above. As shown in Figure 6c , Beclin 1 siRNA transfection inhibited the prevalence of autophagic cells from 62 to 31% in U87-MG cells (Po0.01). Furthermore, transfection with Beclin 1 siRNA significantly reduced the inhibitory effect of rapamycin and mTOR siRNA on the viability of U87-MG cells (Po0.05). These results confirmed that autophagy plays a central role in the loss of cell viability in this setting.
On the other hand, recent investigations showed that mTOR inhibition activates the upstream signaling such as Akt (Shi et al., 2005; O'Reilly et al., 2006) . Therefore, we determined whether rapamycin or mTOR siRNA stimulates the phosphorylation of Akt in malignant glioma cells. As shown in Figure 6d treatment with 100 nM rapamycin for 48 h or 100 nM mTOR siRNA for 48 h did not affect the phosphorylation level of Akt. These results indicated that the upstream molecule of the mTOR was not influenced by rapamycin or mTOR siRNA at least in U87-MG cells.
Discussion
In this study, we demonstrated that rapamycin induced autophagy in malignant glioma cells and that this autophagy mediated the growth inhibitory effect of rapamycin. We also demonstrated that rapamycin treatment did not inhibit the mTOR kinase activity directly. Indeed, the incidence of autophagy induced by rapamycin was enhanced by suppression of the kinase Effect of mTOR siRNA on rapamycin-induced autophagy A Iwamaru et al activity. Furthermore, mTOR siRNA increased the sensitivity of malignant glioma cells to rapamycin by stimulating autophagy regardless of the PTEN status of the tumor cells. These findings suggest that silencing the mTOR signaling pathway is a potential therapeutic strategy with which to sensitize malignant glioma cells to rapamycin. The mechanism for the additive activity of rapamycin and mTOR activity inhibition is not clear. However, it is likely that the inhibition of mTOR activity by the dominant-negative construct or siRNA was not complete and that rapamycin augmented the effects on the raptor-sensitive events downstream of mTOR. Inhibition of mTOR likely initiated additional process dependent on rapamycin-insensitive actions of mTOR such as rictor-dependent processes. mTOR acts as a molecular link between apoptosis and autophagy (Castedo et al., 2002) . mTOR inhibitors induce apoptosis in some types of tumor cells (Hosoi et al., 1999; Nepomuceno et al., 2003; Majumder et al., 2004; Avellino et al., 2005) , whereas they trigger autophagy in other settings (Noda and Ohsumi, 1998; Gutierrez et al., 2004; Kanazawa et al., 2004; Ravikumar et al., 2004) as well as in malignant glioma cells as shown in this study and our previous investigation (Takeuchi et al., 2005) . Autophagy is a process by which cells degrade and recycle proteins and intracellular components in response to stress or starvation (Klionsky and Emr, 2000; Levine and Klionsky, 2004; Shintani and Klionsky, 2004) . A complex of class III PI3K and Beclin 1 at the trans-Golgi network acts to induce autophagy, whereas mTOR, which is a downstream target of the class I PI3K/Akt, inhibits autophagy. However, the direct relationship between Beclin 1 and mTOR is not yet defined. TOR kinase in yeast or mTOR in mammalian cells is considered a gatekeeper for the initiation of the autophagic pathway. On the other hand, in this study, Beclin 1 siRNA transfection inhibited rapamycin-induced autophagy. These suggest that mTOR might be located upstream of Beclin 1.
In cancer research, autophagy is a novel concept, and its therapeutic role remains unclear (Ogier-Denis and Codogno, 2003; Gozuacik and Kimchi, 2004; Kondo et al., 2005) . In this study, we demonstrated that inhibition of rapamycin-induced autophagy by Beclin 1 siRNA attenuated rapamycin's cytotoxicity, indicating that rapamycin-induced autophagy likely mediates, at least in part, the antitumor effects of rapamycin. The extent of autophagy caused by rapamycin was greater in rapamycin-sensitive tumor cells than in rapamycinresistant tumor cells. Moreover, silencing the mTOR signal by siRNA enhanced rapamycin-induced autophagy and concurrently increased rapamycin's cytotoxicity. These findings suggest that the degree of autophagy induced by rapamycin is likely to correlate with its therapeutic efficacy. In general, tumor cells require a higher level of protein synthesis than protein degradation to grow rapidly (Cuervo, 2004) . Indeed, less autophagic degradation is seen in cancer cells than in their normal counterparts. Therefore, autophagy is thought to be a tumor suppressor mechanism (OgierDenis and Codogno, 2003; Gozuacik and Kimchi, 2004; Kondo et al., 2005) based on the findings that Beclin 1 is a haploinsufficient tumor suppressor gene that regulates autophagy (Liang et al., 1999; Qu et al., 2003; Yue et al., 2003) . Because Beclin 1 siRNA inhibited rapamycininduced autophagy and reduced its antitumor effect but did not induce apoptosis in rapamycin-sensitive tumor cells, we speculated that Beclin 1 plays a role in rapamycin-induced autophagy, which suppresses growth of malignant glioma cells.
Accumulating evidence indicates that PTEN-deficient tumor cells are more sensitive to rapamycin than are tumor cells with wild-type PTEN because the loss of PTEN activates a rapamycin-sensitive raptor-mTOR growth pathway (Kim et al., 2002; Guertin and Sabatini, 2005) to which these cells become dependent or addicted. Indeed, in our study, LN229 cells with wildtype PTEN were resistant to rapamycin compared with other malignant glioma cells with mutant PTEN. Strikingly, phosphorylation of p70S6K was equally sensitive to rapamycin in each of the cell lines indicating that inhibition of phosphorylation of p70S6K is insufficient to explain the activity of rapamycin. The mechanism by which rapamycin blocks the phosphorylation of p70S6K but not 4E-BP1 requires additional investigation as rapamycin did not directly inhibit mTOR kinase activity, consistent with the results of another recent investigation (Edinger et al., 2003) . Furthermore, expression of kinase-inactive mTOR increased the effect of rapamycin on malignant glioma cells in this study and on human embryonic kidney HEK 293 cells (Edinger et al., 2003) . These observations suggested that rapamycin does not perturb all mTOR functions and therefore that inhibition of other mTOR functions, such as kinase activity, could require the addition of anticancer agents other than rapamycin to sensitize cells to rapamycin.
In contrast to raptor, rictor was recently identified in both yeast and mammals as a novel mTOR-interacting protein (Loewith et al., 2002) . Unlike its mTOR-raptor sibling, the mTOR-rictor complex does not bind to FKBP12-rapamycin and is insensitive to rapamycin. This discovery provided solid evidence that rapamycin does not completely inhibit mTOR function. In addition, a recent investigation showed that the inhibition of mTOR by rapamycin triggered the activation of survival signaling pathways, including the Akt pathway, and that this activation may contribute to drug resistance (Sun et al., 2005) . This phenomenon provides support for the idea that mTOR has a positive role in regulating Akt phosphorylation that is not shared with raptor but possibly is shared with rictor (Guertin and Sabatini, 2005) . In this study, we succeeded in sensitizing not only rapamycin-sensitive malignant glioma cells but also rapamycin-resistant cells to rapamycin by using mTOR siRNA. Our success could be explained by the effects of dominant-negative mTOR and mTOR silencing on global inhibition of two mTOR complexes. In other words, mTOR siRNA treatment could cause dysfunction of both raptor-mTOR and rictor-mTOR complexes, whereas rapamycin treatment does not induce a complete inhibition of mTOR function. The ability of Effect of mTOR siRNA on rapamycin-induced autophagy A Iwamaru et al rapamycin to increase the activity of dominant-negative mTOR or mTOR siRNA suggests that these approaches do not completely block mTOR function and that rapamycin provides a more complete blockade. Alternatively, rapamycin may mediate functions that are independent of mTOR that are additive with inhibition of mTOR.
In conclusion, we demonstrated that autophagy is required for rapamycin to inhibit the viability of malignant glioma cells. The extent of autophagy induction correlates with the effectiveness of rapamycin, which is supported by a recent investigation showing the negative regulatory effect of Ras oncogene on autophagy and its reversion by rapamycin that induces autophagy in Ras-transformed cells (Furuta et al., 2004) . Moreover, silencing the mTOR signal by siRNA enhances rapamycin's antitumor effect by increasing the extent of autophagy. Strikingly, in our study, this combination regimen sensitizes even rapamycin-resistant tumor cells. Taken together, our results suggest that therapy with both rapamycin and mTOR siRNA is a promising strategy with which to manage malignant gliomas.
Materials and methods

Reagent
Rapamycin was obtained from Sigma Chemical (St Louis, MO, USA). The stock solution was made at a concentration of 1 mM in dimethyl sulfoxide and stocked at À201C.
Cell culture
Human malignant glioma U87-MG and A172 cells with PTEN mutation (Adachi et al., 1999; Morimoto et al., 1999) were purchased from American Type Culture Collection (Manassas, VA, USA). Human malignant glioma D54 cells with mutant PTEN and LN229 cells with wild-type PTEN were kindly supplied by Dr Frederick F Lang and Dr Candelaria GomezManzano (The University of Texas MD Anderson Cancer Center, Houston, TX, USA). Cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA), 4 mM glutamine, 100 U/ml penicillin and 2.5 mg/ml fungizone (Invitrogen) at 371C in 5% CO 2 .
Cell viability assay
The cytotoxic effect of rapamycin was determined using a WST-1 cell proliferation reagent kit (Roche Applied Science, Indianapolis, IN, USA), as described previously (Ito et al., 2005) . Tumor cells in the exponential growth phase were harvested and seeded at 5 Â 10 3 cells per 0.1-ml well in 96-well flat-bottomed plates (Corning, Corning, NY, USA) and incubated overnight at 371C in 5% CO 2 . After exposure to rapamycin (1, 10 or 100 nM) for 24 or 48 h, the cells were incubated with 10% WST-1 cell culture medium for 1 h, and the absorbance of the samples against a background control was measured using a microplate reader. The viability of tumor cells treated with vehicle alone was regarded as 100%.
Western blotting
Soluble proteins were isolated from treated or untreated tumor cells for Western blotting as described previously (Takeuchi et al., 2005) . Equal amounts of protein (20-40 mg) from each sample were separated by electrophoresis through sodium dodecyl sulfate-polyacrylamide gels (Bio-Rad, Richmond, CA, USA) and transferred to a Hybond-P membrane (Amersham, Piscataway, NJ, USA). The membranes were treated with antibodies and subjected to Western blotting using an enhanced chemiluminescence (ECL) or ECL-plus chemiluminescence reagent (Amersham). The primary antibody against b-actin was purchased from Sigma, and the antibodies against total Akt, phospho-Akt (Ser   473   ) , total p70S6K, phospho-p70S6K (Thr 389 ), 4E-BP1, phospho-4E-BP1 (Thr 37/46 ) and mTOR were purchased from Cell Signaling Technology (Beverly, MA, USA). Anti-Beclin 1 antibody was purchased from Novus Biologicals (Littleton, CO, USA). Anti-AU1 antibody was purchased from Covance (Denver, PA, USA).
Electron microscopy
Tumor cells were grown on glass coverslips, treated as described above for the cell viability assay, and fixed with a solution containing 3% glutaraldehyde plus 2% paraformaldehyde in 0.1 M cacodylate buffer, pH 7.3, for 1 h. After fixation, the samples were post-fixed in 1% OsO 4 in the same buffer for 1 h, and then subjected to electron microscopic analysis as described previously (Takeuchi et al., 2005) . Representative areas were chosen for ultrathin sectioning and viewed with a JEM 1010 transmission electron microscope (JEOL, Peabody, MA, USA) at an accelerating voltage of 80 kV. Digital images were obtained using the AMT imaging system (Advanced Microscopy Techniques, Danvers, MA, USA).
Assessment of the involvement of LC3
LC3, a mammalian homolog of Atg8 in yeast, is recruited to the autophagosome membrane during autophagy (Kabeya et al., 2000) . GFP-LC3-expressing cells have been successfully used to demonstrate induction of autophagy by amino-acid deprivation or anticancer treatments (Kabeya et al., 2000; Mizushima et al., 2001; Kanzawa et al., 2005) . GFP-LC3 cells present a diffuse distribution under control conditions, whereas a punctate pattern of GFP-LC3 expression (GFP-LC3 dots) is induced by autophagy. In the current study, we determined the prevalence of autophagic cells (i.e., cells expressing GFP-LC3 dots) by using the GFP-LC3 expression vector kindly provided by Dr Noboru Mizushima (Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan), as described previously (Daido et al., 2005; Kanzawa et al., 2005) . Tumor cells were transiently transfected with this vector by using Fugene 6 transfection reagent (Roche). After overnight culture, the cells were treated with vehicle alone, rapamycin or siRNA for 48-72 h, fixed with 4% paraformaldehyde, and examined under a fluorescence microscope. To quantify autophagic cells after treatment, we counted the number of autophagic cells among 200 GFP-positive cells.
siRNA transfection For siRNA transfection, cells at a concentration of 2.5 or 5 Â 10 4 cells/ml were incubated for 24 h in six-well plates in culture medium. The cells were then transfected with 100 nM Beclin 1, mTOR or non-targeting (random) siRNA (Dharmacon, Lafayette, CO, USA) for 72 h in the presence of Oligofectamine (Invitrogen) and subjected to Western blotting using anti-Beclin 1 or anti-mTOR antibody. The respectively. To determine whether rapamycin-induced autophagy and cytotoxicity are affected by Beclin 1 or mTOR siRNA transfection, tumor cells transfected with 100 nM Beclin 1, mTOR or random siRNA for 24 h were treated with vehicle alone or rapamycin (1-100 nM) for 48 h for the WST-1 assay and the detection of GFP-LC3 dots.
Activity assay of mTOR For mTOR immunoprecipitation, tumor cells treated with vehicle alone or rapamycin (100 nM) for 48 h or LY294002 (5 mM) for 24 h were solubilized in RIPPA lysis buffer (Upstate, Waltham, MA, USA). Then, 100 mg of extracted protein per sample in 500 ml of lysis buffer was immunoprecipitated with anti-mTOR antibody and protein A beads as described previously (Zhang et al., 2003) . Samples were incubated with [g-32 P]ATP (Perkin Elmer, Boston, MA, USA), cold ATP (Sigma) and 4E-BP-1 (Calbiochem, San Diego, CA, USA) in kinase buffer for 30 min and then processed for sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Labeling was visualized by autoradiography.
Transient transfection with kinase-inactive mTOR mutant vector Tumor cells were co-transfected with GFP-LC3 plasmid and AU1 epitope-tagged mTOR mutant vectors (SI and SIDA) (Edinger et al., 2003) , which were kindly provided by Dr Robert T Abraham (Wyeth Research, Pearl River, NY, USA), by using Fugene transfection reagent. Twenty-four hours later, the cells were treated with vehicle alone or rapamycin (100 nM) for 48 h, fixed with 4% paraformaldehyde and were examined under a fluorescence microscope.
Statistical analysis
All experiments were repeated at least three times. The data are expressed as means7standard deviations (s.d.s). Statistical analysis was performed using Student's t-test (two-tailed). The criterion for statistical significance was Po0.05.
